Bone Regeneration Using PRF After Cyst Enucleation

This study is designed as a randomized controlled clinical trial to evaluate the effectiveness of autologous platelet-rich fibrin (PRF) in enhancing bone regeneration after cystic enucleation in the jaws.

PRF is an autologous biomaterial rich in growth factors that may enhance bone healing and tissue regeneration. Participants undergoing cystic enucleation will be randomly assigned to either a PRF-treated group or a control group receiving conventional treatment without PRF.

Clinical and radiographic assessments will be performed to evaluate bone regeneration, healing rate, and postoperative outcomes. If PRF demonstrates significant improvement in osseous regeneration, it may represent a minimally invasive and cost-effective alternative to traditional bone grafting procedures.

Ethical approval will be obtained from the Ethical Committee of the Faculty of Medicine and Health Sciences, Sana'a University, Yemen.

Inclusion criteria

• Patients diagnosed with odontogenic cysts requiring surgical enucleation.
• Presence of a postoperative osseous defect in the jaws after cyst enucleation.
• Age ≥ 18 years.
• Systemically healthy patients (ASA I or II).
• Patients willing to participate and sign informed consent.

Exclusion criteria

• Patients with systemic diseases affecting bone healing (e.g., uncontrolled diabetes, osteoporosis).
• Patients receiving bisphosphonates or long-term corticosteroid therapy.
• Smokers (>10 cigarettes/day).
• Pregnant or lactating women.
• Patients with acute infection at the surgical site.
• Patients unwilling to participate or unable to attend follow-up visits.